2024-08-20 09:14:00
Will Pierre Fabre’s R&D site in Saint-Julien-en-Geneva soon be under Indian ownership? The laboratory announced that it has entered into exclusive negotiations with Jubilant Biosys, a subsidiary of Indian pharmaceutical group Jubilant Pharmnova that specializes in customized development.
Created in 1990, these Savoyard facilities employ 35 people and specialize in immuno-oncology research. “Especially in the biomedical field of macrophage immunomodulation”designated Pierre Fabre. The site also has expertise on ADCs, biologics that are booming in the pharmaceutical industry. The facility is also located in close proximity to Geneva’s vibrant ecosystem. So many reasons for Jubilant Biosys to go on the offensive to acquire these devices. The Indian group therefore wants to expand into this promising field of bioproduction and gain a foothold in Europe. The company, which defines itself as a CRDMO (between CRO and CDMO), already has three R&D facilities in India and a manufacturing base in Nanjangud (India). Pierre Fabre wanted to focus on another treatment approach.
French laboratories have made cancer treatment one of their priorities. Therefore, it invests half of its R&D budget (approximately 200 million euros) every year. For Pierre Fabre, the sale of the Saint-Julien site in the Geneva region would be part of an oncology strategy that focuses more on small molecules and targeted therapies rather than immunotherapies.
The strategy is also based on external growth operations. Last March, Pierre Fabre purchased the rights to a molecule from biotech company Kinnate Biopharma. In conjunction with the sale of the Savoy site, the laboratory hopes to concentrate its research activities around its Toulouse center on the Oncopole campus.
“Negotiations involve taking over the site, its 35 staff, buildings and equipment as well as current research projects”designated laboratory. The sale will involve the creation of a company to house the assets of the Saint-Julien site in the Geneva region, in which Jubilent Biosys will become the majority shareholder, while Pierre Fabre has committed to retain a minority stake for five years.
If the project is currently being negotiated with employee representatives and on-site staff, the two partners hope to have operations completed by the end of the year. Until 2020, Pierre Fabre also owned a production site in Saint-Julien-en-Geneva, which was eventually sold to Fareva.
1724164146
#Pierre #Fabre #base #established #India
